AdipoGen Life Sciences

Rilpivirine

CHF 60.00
In stock
AG-CR1-3750-M0055 mgCHF 60.00
AG-CR1-3750-M02525 mgCHF 240.00
More Information
Product Details
Synonyms R278474; TMC278; DB08864
Product Type Chemical
Properties
Formula

C22H18N6

MW 366.4
CAS 500287-72-9
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (25mg/ml). Warming and sonication may be needed.
Identity Determined by 1H-NMR.
InChi Key YIBOMRUWOWDFLG-ONEGZZNKSA-N
Smiles CC1=CC(/C=C/C#N)=CC(C)=C1NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51nM. It is active against NNRTI-resistant HIV strains with EC50 values less than 1nM for L100I, K103N, V106A, G190A and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = <10nM), including strains containing up to eight resistance mutations.
  • NNRTIs work by binding to and blocking HIV reverse transcriptase, which prevents HIV from replicating and lowers the amount of HIV in the blood.
  • Rilpivirine is an antiviral anti-HIV drug, active against wild-type and NNRTI-resistant HIV-1 with higher potency, longer half-life and reduced side-effect profile compared with Efavirenz (Prod. No. AG-CR1-3751).
  • CARD8 inflammasome senses HIV-1 protease activity. In HIV1-infected cells, CARD8 cannot detect the virus because the viral protease remains inactive as a subunit of unprocessed Gag-Pol polyprotein. HIV-1-specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), such us Rilpivirine, can trigger CARD8 sensing because they bind to HIV-1 Pol and enhance intracellular Gag-Pol polyprotein dimerization, which causes premature viral protease activation. Treating HIV-1-infected macrophages and CD4+ T cells with NNRTIs leads to CARD8-mediated caspase-1 activation and pyroptotic cell death. Induction of the CARD8 inflammasome activation has led to rapid clearance of latent HIV-1 in patient CD4+ T cells after virus reactivation.
Product References
  1. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1: J. Guillemont, et al.; J. Med. Chem. 48, 2072 (2005)
  2. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine): P.A. Janssen, et al.; J. Med. Chem. 48, 1901 (2005) (Review)
  3. Short-term antiviral activity of TMC278 -a novel NNRTI- in treatment-naive HIV-1-infected subjects: F. Goebel, et al.; AIDS 20, 1721 (2006)
  4. Rilpivirine: A novel non-nucleoside reverse transcriptase inhibitor: L. Garvey & A. Winston; Expert Opin. Drug Discov. 18, 1035 (2009)
  5. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1: H. Azijn, et al.; Antimicrob. Agents Chemother. 54, 718 (2010)
  6. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review: J.J. Schafer & W.R. Short; Antivir. Ther. 17, 1495 (2012) (Review)
  7. Biochemical Mechanism of HIV-1 Resistance to Rilpivirine: K. Singh, et al.; J. Biol. Chem. 287, 38110 (2012)
  8. Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response: J. Vingerhoets, et al.; Antivir. Ther. 18, 253 (2013)
  9. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy: M. Arainga, et al.; Retrovirology 14, 17 (2017)
  10. CARD8 is an inflammasome sensor for HIV-1 protease activity: Q. Wang, et al.; Science 371, 6535 (2021)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.